难治性部分性癫痫应用加巴喷丁添加治疗的疗效及安全性分析

doi:10.3969/j.issn.1006-6233.2017.06.013

摘要
图/表
参考文献(17)
相关文章 (11)

全文: PDF (1427 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探究难治性部分性癫痫应用加巴喷丁添加治疗的疗效及安全性。方法: 收集我院神经内科收治的难治性部分性癫痫患者70例,随机分为试验组和对照组,各35例。对照组患者予以卡马西平片起始剂量为5mg/kg每日,可逐渐增至20mg/kg;托吡酯片起始剂量为0.8mg/kg每日,可逐渐增至7mg/kg。试验组患者在维持对照组用药的基础上添加加巴喷丁胶囊,第1日加巴喷丁胶囊300mg口服每次,每日1次,第二日剂量加巴喷丁胶囊300mg口服每次,每日2次,第3天直至疗程结束为加巴喷丁胶囊300mg口服每次,每日3次。两组患者疗程均为6个月。治疗结束后对两组患者临床疗效、记忆功能、神经功能缺损程度、T淋巴细胞群、血清免疫球蛋白及不良反应发生情况进行对比。结果: 治疗后,与基线期发作频率相比,两组4周后发作频率以及12周后发作频率较低;与治疗前相比,治疗后两组CMS得分升高,NFDS得分降低,IgA、IgG以及IgM水平降低,血清CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺升高(P＜0.05)。与对照组相比,试验组临床总有效率较高,4周后、12周后发作频率较低,CMS得分较高,NFDS得分较低,IgA、IgG以及IgM水平较低,血清CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺较高,不良反应发生率较低,差异具有统计学意义(P＜0.05)。两组治疗前后CD⁸⁺相比,差异无统计学意义(P＞0.05)。结论: 加巴喷丁添加治疗难治性部分性癫痫的临床疗效显著,能够改善患者记忆功能、神经功能及免疫功能,安全性高,适宜临床应用推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：难治性部分性癫痫, 加巴喷丁, 临床有效率, 安全性

Abstract：Objective: To investigate the efficacy and safety analysis of Gaba Martin Add treatment in the treatment of Refractory partial epilepsy patients. Method: 70 Refractory partial epilepsy patients admitted to neurology department of our hospital were selected and randomly divided into the control group and the experiment group with 35 cases in each group. The control group was given a Carbamazepine Tablets starting dose of 5mg/kg daily, gradually increased to 20 mg/kg. Topiramate Tablets starting dose of 0.8mg/kg per day could be gradually increased to 7mg/kg. The patients in the experimental group were added gabapentin Capsule on the basis of the control group. First gabapentin capsules 300mg orally every time, 1 times a day, second doses of gabapentin capsules 300mg orally every day, 2 times a day, third days until the end of treatment for gabapentin capsules 300mg oral every time, 3 times a day. Two groups of patients were treated for a period of 6 months. After treatment, the clinical efficacy, memory function, the degree of neurological deficit, T lymphocyte group, serum immunoglobulin and adverse reactions were compared between the two groups. Results: After treatment, 2 weeks after the onset of the attack frequency and the frequency of attack after 12 weeks was lower than the baseline frequency. Compared with before treatment, after treatment, the 2 groups of CMS score increased, NFDS score decreased, IgA, IgG and IgM levels decreased, serum CD³⁺, CD⁴⁺, CD⁴⁺/ CD⁸⁺ increased(P＜0.05). Compared with the control group, the total effective rate of treatment group was higher after 4 weeks, 12 weeks after the onset of lower frequency, higher CMS scores, lower NFDS score, IgA, IgG and IgM low level of serum CD³⁺, CD⁴⁺, CD⁴⁺/, CD⁸⁺ high and low incidence rate of adverse reaction, the difference has statistical significance(P＜0.05). There was no significant difference between the 2 groups before and after treatment with CD⁸⁺(P＞0.05). Conclusion: The clinical efficacy of gabapentin in the treatment of refractory partial epilepsy is significant. It can improve the memory function, nerve function and immune function of patients.

Key words： Refractory partial epilepsy Gaba martin Clinical efficacy Safety

基金资助:山东省卫生厅科研项目,(编号:2013ZR2786)

引用本文:

邵广田, 邵璐斐, 陈霄雷, 任显芝, 崔凤荣. 难治性部分性癫痫应用加巴喷丁添加治疗的疗效及安全性分析[J]. 河北医学, 2017, 23(6): 923-926.
SHAO Guangtian, et al. Efficacy and Safety Analysis of Gaba Martin Add treatment in the Treatment of Refractory Partial Epilepsy Patients. 河北医学, 2017, 23(6): 923-926.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2017.06.013 或 http://www.hbyxzzs.cn/CN/Y2017/V23/I6/923

[1] 林志刚,冯建华,潘慧.左乙拉西坦添加治疗儿童部分性或全面性癫痫19例临床分析[J].中国基层医药,2014,21(4):608~609.
[2] 王文志,吴建中,王德生,等.中国五省农村人群癫痫流行病学抽样调查[J].中华医学杂志,2002,82(7):449~452.
[3] 黄颖,杜华斌,杨申,等.宁夏青铜峡地区人群癫痫流行病学及药物治疗的调查研究[J].陕西医学杂志,2008,37(8):1068~1070.
[4] 王欣,薛朝霞.加巴喷丁的药理学及其在疼痛临床的应用进展[J].实用疼痛学杂志,2010,06(2):129~133.
[5] 杨牧,周红,陈超.基于分子靶点分析抗癫痫中药作用机制的研究[J].中药药理与临床,2006,22(5):63~64.
[6] 吴逊,李文慧.国际抗癫痫联盟和名词委员会推荐的癫痫发作的临床及脑电图分类[J].中华神经科杂志,2001,34(3):187~188.
[7] 吴立文,邓施平,彭炳蔚.癫痫及癫痫综合征国际分类(1989年)的临床应用分析[J].中华神经科杂志,2005,38(6):370~372.
[8] 李世绰,吴立文.临床诊疗指南:癫痫病分册[M].人民卫生出版社,2007.47~35.
[9] 刘之红,刘之英.35例癫痫患者的康复指导[J].中国实用医药,2012,7(7):237~238.
[10] 继成.世界抗癫痫药物研究开发最新进展[J].中国制药信息,2007,23(6):8~11.
[11] 田元元,黄希顺,陈晨,等.左乙拉西坦治疗部分性发作癫痫持续状态2例报告并文献复习[J].神经损伤与功能重建,2014,9(3):265~266.
[12] 聂光军,初凤娜,崔俐,等.拉莫三嗪对癫痫患者认知功能影响的研究[J].中风与神经疾病,2012,29(10):930~931.
[13] 陈宝泉,刘肖英,李彩文.新型抗癫痫药加巴喷丁[J].中国新药杂志,2007,16(11):900~902.
[14] 臧颖卓,王维平,刘瑞春,等.加巴喷丁对癫痫大鼠海马神经元及P75NTR表达的影响[J].山西医药杂志,2016,45(17):2000~2002.
[15] 冯艺,崔明磊,William D.WILLIS.抗惊厥药加巴喷丁抑制内脏疼痛的作用及其与脊髓氨基酸递质释放的关系[J].北京大学学报医学版,2003,35(3):307~310.
[16] 邹功胜,胡兴国,孔明,等.鞘内注射加巴喷丁和/或吗啡对切口痛大鼠脊髓氨基酸含量的影响[J].国际麻醉学与复苏杂志,2009,30(4):332~334.
[17] 谢娜,邓建中,申长发,等.加巴喷丁胶囊单药治疗癫痫感觉性部分发作的临床研究[J].中国实用医药,2016,11(7):187~188.